FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPROVAL										
	OMB Number:	3235-028									
-	Estimated average burden										

37 hours per response: 0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BOGER JOSHUA S					VI	2. Issuer Name and Ticker or Trading Symbol  VERTEX PHARMACEUTICALS INC /  MA [ VRTX ]										eck all a		*		on(s) to Issu 10% Ow		
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET					3. E 08/	3. Date of Earliest Transaction (Month/Day/Year) 08/16/2005										X Officer (give title Other (specify below) Chairman, President & CEO						
(Street) CAMBR (City)			02139 (Zip)		4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)										e) <mark>X</mark> Fo Fo	ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																						
D.				2. Transaction Date (Month/Day/Year)		ear) i	2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			4 and Securition Benefici		s Illy ollowing	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
										Code	v	Amount		(A) or (D)	Price	Tran	sacti	ion(s) ind 4)		[	(Instr. 4)	
Common Stock 08/16					5/200	/2005						7,100		A	\$9.5		995,302			D		
Common Stock 08/16					6/200	5				S <sup>(1)</sup>		7,100		D	\$16.8	2	988,202		D			
Common Stock																	207	,500			shares in trust <sup>(2)</sup>	
Common Stock																	10,	920		I	401(k)	
		7	Table II -									sed of, onvertil				Owne	d					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transaction Code (Instr. 8)				Ex	Date Exe piration onth/Day	Date		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			Derivat Securit	B. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dat Exe	te ercisable		expiration Date	Title		Amount or Number of Shares							
Stock Option	\$9.5	08/16/2005			A		7,100 03			14/1996	(3) 1	2/13/2005	Common Stock 7,1		7,100	\$0		1,547,211		D		

#### **Explanation of Responses:**

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- $2. \ Shares \ held \ in \ trust \ for \ Dr. \ Boger's \ children. \ Dr. \ Boger \ disclaims \ beneficial \ ownership \ of \ such \ shares.$
- 3. Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/95.

### Remarks:

Kenneth S. Boger, Attorney-In-08/17/2005

**Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.